Ionic channesls and second messenger alterations in Alzheimer's disease. Relevance of studies in non-neuronal cells;Alteraciones de canales iónicos y segundos mensajeros en la enfermedad de Alzheimer. Relevancia de estudios en células extraneurales

Revista de Neurologia

Volumn 33, Issue 8, 2001, Pages 740-749

  Etcheberrigaray, René ^a   Ibarreta, D ^a  

^a NeuroLogic Inc   (United States)

Author keywords

Alzheimer's disease; Calcium; Fibroblasts; Ion channels; Protein kinnase C; Second messengers

Indexed keywords

CALCIUM ION; ION CHANNEL; PROTEIN KINASE C;

ALZHEIMER DISEASE; CADAVER; CALCIUM HOMEOSTASIS; CENTRAL NERVOUS SYSTEM; CLINICAL FEATURE; CONTROLLED STUDY; FIBROBLAST; HUMAN; HUMAN TISSUE; NERVE CELL; PATHOPHYSIOLOGY; REVIEW; SIGNAL TRANSDUCTION;

EID: 0035900095     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.3308.2001342     Document Type: Review

References (153)

1. Projections of Alzheimer's disease in the United States and public health impact of delaying disease onset
2. Las memorias y la enfermedad de Alzheimer
3. Alzheimer's disease: Genes, proteins and therapy
4. Original paper by Alois Alzheimer: Translation
5. Alzheimer's disease: Initial report of the purification and characterization of a novel cerebrovascular amyloid protein
6. The gene defects responsible for familial Alzheimer's disease
7. Alzheimer's disease: Genotypes, phenotype and treatments
8. Amyloid, the presenilins and Alzheimer's disease
9. Exploring the etiology of Alzheimer disease using molecular genetics
10. Transplanting cell biology into therapeutic advances in Alzheimer's disease
11. Modeling Alzheimer's disese in trasgenic mice: Effect of age and of presenilin 1 on amyloid biochemistry and pathology in APP/london mice
12. Trasgenic Mouse models of Alzheimer's disease
13. Altered oxidation and signal transduction systems in fibroblasts from Alzheimer patients
14. Systemic manifestations of Alzheimer's disease
15. Extraneuronal manifestations of Alzheimer's disease
16. Use of cultured fibroblasts in elucidating the pathophysiology and diagnosis of Alzheimer's disease
17. Peripheral markers in testing pathophysiological hypotheses and diagnosing Alzheimer's disease
18. Fibroblast models of neurological disorders: Fluorescence measurement studies
19. An enzyme defect associated with a sex-linked human neurological disorder and an excessive purine synthesis
20. Tay-Sachs disease: Generalized absence of a beta-d-N-acetylhexosaminidase component
21. Ionic and signal trasduction Alterations in Azheimer Disease: Relevance of studies in peripheral cells
22. Recent advances in cystic fibrosis
23. + currents in neurons: Types, physiological roles and modulation
24. Potassium channels in neuropsychiatric disorders: Potential for pharmacological intervention
25. Ion channels and diseases
26. Calcium-mediated reduction of ionic currents: A biophysical memory trace
27. Sequential modification of membrane currents with classical conditioning
28. Voltage-clamp analysis ofthe effects of classical conditioning on the hippocampus
29. Serotonin modulates a specific potassium current in the sensory neurons that show presynaptic facilitation in Aplysia
30. Potassium channel dysfunction in fibroblasts identifies patients with Alzheimer disease
31. + channels
32. Rapid cellular intake of Alzheimer amyloid betaA4 peptide by cultured human neuroblastoma cells
33. Restoration of TEA-induced calcium responses in fibroblasts from Alzheimer's disease patients by a PKC activator
34. Benzolactam (BL) enhances sAPP secretion in fibroblasts and PC12 cells
35. + channels in Alzheimer's disease
36. Abnormal function of potassium channels in platelets of patients with Alzheimer's disease
37. The effect of tetraethylammonium on intracellular calcium concentration in Alzheimer's disease fibroblasts with APP, S182 and E5-1 missense mutations
38. Tetraethylammonium-induced calcium concentration changes in skin fibroblasts from patients with Alzheimer disease
39. + current in rat hippocampal neurons
40. + channels and suppression of neural activity by secreted betaamyloidprecursor protein
41. + currents of human T-lymphocytes are unaffected by Alzheimer s disease and amyloid beta protein
42. Single K channles in acutely dissociated hippocampal neurons from transgenic B6SJLF1 mice
43. Early phenotipic changes in trasgenic mice that overexpress different mutants of amyloid precursor protein in brain
44. Selective reduction of [125I]apamin binding sites in Alzheimer hippocampus: A quantitative autoradiographic study
45. Differential alterations of ion channel binding sites in temporal and occipital regions of the cerebral cortex in Alzheimer's disease
46. Amyloid beta peptides act directly on single neurons
47. Beta-Amyloid increases choline conductance of PC12 cells: Possible mechanism of toxicity in Alzheimer's disease
48. Membrane currents induced in Xenopus oocytes by the C-terminal fragment of the beta-amyloid precursor protein
49. 2+ channels: A possible involvement of free radicals
50. 2+-permeable channels through calcium-sensing receptor
51. Ionic effects of the Alzheimer s disease beta-amyloid precursor protein and its metabolic fragments
52. Giant multilevel cation channels formed by Alzheimer disease amyloid beta-protein [A beta P-(1-40)] in bilayer membranes
53. Channel formation in planar lipid bilayers by a neurotoxic fragment of beta-amyloid peptide
54. + channel blockers attenuate beta-amyloid peptide toxicity to cortical neurons in culture
55. Alzheimer amyloid beta-peptides exhibit ionophore-like properties in human erythrocytes
56. 2+-sensitive, cation-selective channels across excised membrane patches form hypothalamic neurons
57. 2+-sensitive channel
58. 2+ homeostasis in Alzheimer's disease
59. Calcium hypothesis of Alzheimer's disease and brain aging
60. Calcium alterations in Alzheimer's disease: Pathophysiology, models and therapeutic opportunities
61. Cytosolic free calcium and cell spreading decrease in fibroblasts from aged and Alzheimer donors
62. 2+]I transients are similar in fibroblasts from normal and Alzheimer's donors
63. 2+-mobilization is altered in fibroblasts from patients with Alzheimer's disease
64. Altered response of fibfoblasts from aged and Alzheimer donors to drugs that elevate cytosolic free calcium
65. Serumand bradykinin-induced calcium transients in familial Alzheimer's fibroblasts
66. Cell-cycle dependent abnormal calcium response in fibroblasts from patients with familial Alzheimer's disease
67. Calcium responses in human fibroblasts: A diagnostic molecular profile for Alzheimer's disease
68. Abnormalities in Alzheime's disease fibroblasts bearing the APP670/671 mutation
69. Protein kinase C levels and amyloid precursor protein processing in skin fibroblasts from sporadic and familial Alzheimer's disease cases
70. Increased sensitivity to mitochondrial toxn-induced apoptosis in neuronal cells expressing mutnmat presenilin-1 is linked to perturbed homeostasis and enhanced oxradical production
71. Presenilins, the endoplasmic reticulum, and neuronal apottosis in Alzheimer's disease
72. Presenilin 2 mutations modulate amplitude and kinetics of isositol 1,4,5, trisphosphate-mediated calcium signals
73. Presenilin-mediated modulation of capacitive calcium entry
74. Mutant presenilins disturb neuronal calcium homeostasis in the brain of transgenic mice, decreasing the threshold for excitotoxicity and facilitating long-term potentiation
75. Increased inositol 1,4,5-trisphosphate accumulation correlates with an upregulation of bradykinin receptors in Alzheimer's disease
76. Amyloid beta peptide enhanced bradykinin-mediated inositol (1, 4, 5) triphosphate formation and cytosolic free calcium
77. 2+ responsiveness in PC12 cells expressing the C-100 fragment of APP
78. Increased cytosolic free calcium in lymphocytes of Alzheimer patients
79. 2+ homeostasis in lymphoblasts from patients with late-onset Alzheimer's disease
80. Cytosolic free calcium in mononuclear blood cells from demented patients and healthy controls
81. Calcium ion transients in neutrophils from patients with sporadic Alzheimer's disease
82. Platelet cytosolic free-calcium concentration is increased in aging and Alzheimer's disease
83. Cytosolic calcium alterations in platelets of patients with early stages of Alzheimer's disease
84. Protein kinase C: Structure, function, and regulation
85. Protein Kinase C isoenzymes: A review of their structure, regulation and role in regulating airways smooth muscle tone and mitogenesis
86. + channels by cytoplasmic and membraneassociated C-kinase
87. Protein kinase C: A nexus in the biochemical events that underlie associative learning
88. Age-related alterations of PKC, a key enzyme in memory processes: Physiological and pathological examples
89. Elimination of rapid potassium channel inactivation by phosphorylation of the inactivation gate
90. + current in human rabbit ventricular myocytes
91. The potential for isoenzyme-selectiv modulation of protein kinase C
92. Biology of the protein kinase C family
93. Phorbol ester binding sites in human brain: Characterization, regional distribution, age-correlation, and alterations in Parkinson's disease
94. Decreased levels of protein kinase C in Alzheimer brain
95. Differential involvement of protein kinase C isozymes in Alzheimer's disease
96. Assessment ofprotein kinase C isozymes by two -site enzyme immunoassay in human brains and changes in Alzheimer's disease
97. Attenuated protein kinase C activity and translocation in Alzheimer's disease brain
98. Protein kinase C alteration is an early biochemical marker in Alzheimer's disease
99. Assessment of protein kinase C mRNA levels in Alzheimer's disease brains
100. Autoradiographic imaging of [3 H] phorbol 12,13-dibutyrate binding to protein kinase C in Alzheimer's disease
101. Characterization and distribution of the three major human protein kinase C isozymes (PKCα, PKCβ, PKCγ) of the central nervous system in normal and Alzheimer s disease brains
102. Reduced protein kinase C immunoreactivity and altered protein phosphorylation in Alzheimer's disease fibroblasts
103. Cytosol protein kinase C downregulation in fibroblasts from Alzheimer's disease patients
104. Reduced protein kinase C immunoreactivity in fibroblasts from patients with Alzheimer's disease
105. Defective Protein Kinase C alpha leads to impaired secretion of soluble beta-amyloid precursor protein from Alzheimer s disease fibroblasts
106. Processing of Alzheimer A beta-amyloid precursor protein: Cell biology, regulation, and role in Alzheimer disease
107. Amyloid beta peptide formation in cell free preparations: Regulation by protein kinase C, calmodulin, and calcineurin
108. Intracellular cyclic AMP inhibits constitutive and phorbol ester-stimulated secretory cleavage of amyloid precursor protein
109. Conventional protein kinase C (PKC)-alpha and novel PKC epsilon, but not -delta, increase the secretion of an N-terminal fragment of Alzheimer's disease amyloid precursor protein from PKC cDNA transfected 3Y1 fibroblasts
110. Regulation ofamyloid precursor protein (APP) secretion by protein kinase calpha in human ntera 2 neurons (NT2N)
111. Blockade of PKC epsilon activation attenuates phorbol ester-induced increase of alpha-secretase-derived secreted form of amyloid precursor protein
112. Protein kinase Calpha and betal isoforms are regulators of alpha-secretory proteolytic processing of amyloid precursor protein in vivo
113. Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE
114. Protein kinase C-dependent alpha-secretase competes with beta-secretase for cleavage of amyloid-beta precursor protein in the trans-golgi network
115. Intracellular Production of betaA4 Amyloid of Alzheimer s disease: Modulation by phosphoramidon and lack of coupling to the secretion of the amyloid precursor protein
116. Protein kinase C activation increases release of secreted amyloid precursor protein without decreasing Abeta production in human primary neuron cultures
117. Turnover of amyloid beta-protein in mouse brain and acute reduction of its level by phorbol ester
118. Modeling, chemistry, and biology of the benzolactam analogues of ILV. 2. Identification of the binding site of the benzolactams in the CRD2 activator-binding domain of PKCdǒ and discovery of an ILV analogue of improved isozyme selectivity
119. Defective phorbol ester-stimulated secretion of beta-amyloid precursor protein from Alzheimer's disease fibroblasts
120. Excessive production of amyloid beta-protein by peripheral cells of symptomatic and presymptomatic patients carrying the Swedish familial Alzheimer disease mutation
121. Increased beta-amyloid release and levels of amyloid precursor protein (APP) in fibroblast cell lines form family members with the Swedish Alzheimer s disease APP690/671 mutation
122. Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer s disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer s disease
123. betaAPP mRNA transcription is increased in cultured fibroblasts from the familial Alzheimer s diseasel family
124. Expression of amyloid beta-protein precursor mRNAs in cultured skin fibroblasts taken from patients with dementia of the Alzheimer type
125. Deficient repair of DNA lesions in Alzheimer's disease fibroblasts
126. Alzheimer disease fibroblasts are hypersensitive to the lethal effects of a DNA-damaging chemical
127. DNA repair deficiency for alkylation damage in cells from Alzheimer's disease patients, in Alzheimer's Disease and Related Disorders
128. DNA damage and repair in telomeres: Relation to aging
129. Studies of biochemical changes in cultured skin fibroblasts derived from sporadic and familial Alzheimer's disease individuais: Qualitative and quantitative changes in double-stranded DNA-stimulated phosphorylation of endogenous nucleoproteins
130. mRNA levels and methylation pattems of the 2-5A synthetase gene in control and Alzheimer's disease fibroblasts
131. Decreased adhesiveness of Alzheimer s disease fibroblasts: Is amyloid beta-protein precursor involved?
132. Changes in adhesion efficiency and vimentin distribution of fibroblasts from familial Alzheimer's disease patients
133. Change in the cytoskeletal system in fibroblasts from patients with familial Alzheimer's disease
134. Study of cytoskeletal proteins in fibroblasts cultured from familial Alzheimer's disease
135. Increased spectrin proteolysis in fibroblasts from aged and Alzheimer donors
136. Occurrence of transkelotase abnormalities in extracts of foreskin fibroblasts from patients with Alzheimer's disease
137. Enhanced proteolytic activities in cultured fibroblasts of Alzheimer patients are revealed by peculiar transkelotase alterations
138. Proteolytic imbalance in Alzheimer fibroblasts as potential pathological trait of disease
139. Reduced activities of thiamine-dependent enzymes in the brains and peripheral tissues of patients with Alzheimer's disease
140. Signal transduction abnormalities in Alzheimer's disease: Evidence of a pathogenic stimuli
141. Activation of cell-cycle-associated proteins in neuronal death: A mandatory or dispensable path?
142. Cell cycle-dependent regulation of the phosphorylation and metabolism of the Alzheimer amyloid precursor protein
143. A possible role for the Alzheimer amyloid precursor protein in the regulation of epidermal basal cell proliferation
144. + exchanger
145. Cyclin' toward dementia: Cell cycle abnormalities and abortive oncogenesis in Alzheimer disease
146. Consensus report of the Working Group on: Molecular and Biochemical markers of Alzheimer's disease
147. Diagnostic approaches to Alzheimer's disease
148. Some remarks on biological markers of Alzheimer's disease
149. Calcium responses are altered in fibroblasts from Alzheimer's patients and pre-symptomatic PS1 carriers: A potential tool for early diagnosis
150. Estrategias terapéuticas en la enfermedad de Alzheimer: Concepto ad continuum
151. Factors influencing the processing and function of the amyloid beta precursor protein: A potential therapeutic target in Alzheimer s disease?